The Tapering Dose of Luspatercept in Patients With Lower-risk Myelodysplastic Syndromes
Status:
RECRUITING
Trial end date:
2026-09-30
Target enrollment:
Participant gender:
Summary
This is a prospective, single center, single-arm, phase 2 study. The aim of this study is to evaluate the efficacy and safety of Luspatercept for Patients with Lower-risk Myelodysplastic Syndromes (MDS).
Phase:
PHASE2
Details
Lead Sponsor:
Institute of Hematology & Blood Diseases Hospital, China